Van K. Morris
About
Van K. Morris is a scholar working on Oncology, Pathology and Forensic Medicine and Surgery.
According to data from OpenAlex, Van K. Morris has authored 162 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Oncology, 65 papers in Pathology and Forensic Medicine and 55 papers in Surgery. Recurrent topics in Van K. Morris's work include Colorectal Cancer Treatments and Studies (97 papers), Genetic factors in colorectal cancer (60 papers) and Cancer Genomics and Diagnostics (49 papers). Van K. Morris is often cited by papers focused on Colorectal Cancer Treatments and Studies (97 papers), Genetic factors in colorectal cancer (60 papers) and Cancer Genomics and Diagnostics (49 papers). Van K. Morris collaborates with scholars based in United States, Brazil and Italy. Van K. Morris's co-authors include Scott Kopetz, Dipen M. Maru, Michael J. Overman, Cathy Eng, Arvind Dasari, Kanwal Raghav, Bryan K. Kee, Filip Jankú, Jean‐Pierre J. Issa and Jayesh Desai and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.
In The Last Decade
Van K. Morris
148 papers receiving 3.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Van K. Morris United States | 28 | 2.3k | 1.1k | 913 | 840 | 773 | 162 | 3.1k | ||
| Sara De Dosso Switzerland | 21 | 3.0k 1.3× | 1.1k 1.0× | 777 0.9× | 1.1k 1.3× | 806 1.0× | 57 | 3.6k | ||
| Yuan‐Tzu Lan Taiwan | 30 | 1.5k 0.6× | 530 0.5× | 544 0.6× | 833 1.0× | 814 1.1× | 108 | 2.6k | ||
| Hisato Kawakami Japan | 32 | 2.7k 1.2× | 666 0.6× | 508 0.6× | 1.6k 1.9× | 834 1.1× | 179 | 3.8k | ||
| Cristiana Lupi Italy | 18 | 1.7k 0.7× | 608 0.5× | 370 0.4× | 631 0.8× | 708 0.9× | 35 | 2.8k | ||
| J. Randolph Hecht United States | 22 | 2.8k 1.2× | 617 0.5× | 501 0.5× | 1.9k 2.2× | 949 1.2× | 78 | 4.2k | ||
| Katia Bencardino Italy | 24 | 1.8k 0.8× | 669 0.6× | 591 0.6× | 806 1.0× | 592 0.8× | 77 | 2.4k | ||
| Syma Iqbal United States | 29 | 2.0k 0.9× | 539 0.5× | 358 0.4× | 993 1.2× | 901 1.2× | 129 | 3.1k | ||
| Emily Chan United States | 20 | 2.1k 0.9× | 471 0.4× | 420 0.5× | 762 0.9× | 1.1k 1.4× | 46 | 2.9k | ||
| Frédérique Penault–Llorca France | 10 | 2.3k 1.0× | 823 0.7× | 1.4k 1.5× | 734 0.9× | 707 0.9× | 20 | 3.3k | ||
| Fabio Gelsomino Italy | 19 | 2.3k 1.0× | 947 0.8× | 506 0.6× | 519 0.6× | 396 0.5× | 71 | 2.8k |
Countries citing papers authored by Van K. Morris
Since
Specialization
Citations
This map shows the geographic impact of Van K. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Van K. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Van K. Morris more than expected).
Fields of papers citing papers by Van K. Morris
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Van K. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Van K. Morris. The network helps show where Van K. Morris may publish in the future.
Co-authorship network of co-authors of Van K. Morris
This figure shows the co-authorship network connecting the top 25 collaborators of Van K. Morris. A scholar is included among the top collaborators of Van K. Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Van K. Morris. Van K. Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Qiao, Wei, Keyur Patel, Deepak Bhamidipati, et al.. (2025). Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors. Nature Communications. 16(1). 4514–4514.
2.
Morris, Van K., Suyu Liu, Kangyu Lin, et al.. (2025). Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal. Clinical Cancer Research. 31(9). 1657–1666.
3.
Shroff, Rachna T., Van K. Morris, Kangyu Lin, & Pamela L. Kunz. (2024). Evaluating speaker gender in scientific sessions at ASCO and ASCO GI (2019-2023).. Journal of Clinical Oncology. 42(16_suppl). 9009–9009.
4.
Morris, Van K., Weihong Xiao, Emma B. Holliday, et al.. (2024). Time dependency for HPV ctDNA detection as a prognostic biomarker for anal cancer.. Journal of Clinical Oncology. 42(16_suppl). 3513–3513.
5.
Morris, Van K., Stefania Napolitano, Christopher A. Bristow, et al.. (2024). Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. Clinical Cancer Research. 30(22). 5166–5179.
6.
Kelly, Ronan J., Katherine M. Bever, Joseph Chao, et al.. (2023). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. Journal for ImmunoTherapy of Cancer. 11(6). e006658–e006658.
7.
Rooney, Michael K., Prajnan Das, Ethan B. Ludmir, et al.. (2023). Salvage Treatment of Recurrent or Persistent Anal Squamous Cell Carcinoma: The Role of Multi-modality Therapy. Clinical Colorectal Cancer. 23(1). 85–94.
8.
Thomas, Jane V., Kaysia Ludford, Jason Willis, et al.. (2023). Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Research Communications. 3(12). 2510–2517.
9.
Napolitano, Stefania, Aparna R. Parikh, Jason T. Henry, et al.. (2023). Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precision Oncology. 7(7). e2300228–e2300228.
10.
Bent, Andrew F., Andrew J. Pellatt, Kristin Alfaro-Munoz, et al.. (2023). 587P Short lead time and high rates of concomitant radiographic recurrences for ctDNA-based minimal residual disease assays colorectal cancer (CRC) during surveillance: Results from the MD Anderson INTERCEPT program. Annals of Oncology. 34. S427–S427.
11.
Sorokin, Alexey V., Preeti Kanikarla Marie, Ganiraju C. Manyam, et al.. (2022). Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6. Cancer Research. 82(18). 3335–3344.
12.
Rogers, Jane E., Hyunsoo Hwang, Wei Qiao, et al.. (2022). Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. The Oncologist. 27(11). 952–957.
13.
Corrigan, Kelsey L., Michael K. Rooney, Brian De, et al.. (2022). Patient-Reported Sexual Function in Long-Term Survivors of Anal Cancer Treated With Definitive Intensity Modulated Radiation Therapy and Concurrent Chemotherapy. Practical Radiation Oncology. 12(5). e397–e405.
14.
Parseghian, Christine M., Ryan Sun, Stefania Napolitano, et al.. (2022). Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. Journal of Clinical Oncology. 41(3). 460–471.
15.
Tchakarov, Amanda, et al.. (2022). The Use of Rituximab in Treatment of Immune Checkpoint Inhibitor Induced Glomerulonephritis. Journal of the American Society of Nephrology. 33(11S). 374–374.
16.
Holliday, Emma B., Van K. Morris, Benny Johnson, et al.. (2022). Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. The Oncologist. 27(1). 40–47.
17.
Chu, Jenny E., Benny Johnson, Van K. Morris, et al.. (2020). Population-based Screening for BRAF V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. Clinical Cancer Research. 26(17). 4599–4605.
18.
Morris, Van K., Xiayu Rao, Curtis R. Pickering, et al.. (2017). Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. Molecular Cancer Research. 15(11). 1542–1550.
19.
Loree, Jonathan M., Allan Andresson Lima Pereira, Michael Lam, et al.. (2017). Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clinical Cancer Research. 24(5). 1062–1072.
20.
Kopetz, Scott, Jayesh Desai, Emily Chan, et al.. (2015). Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer. Journal of Clinical Oncology. 33(34). 4032–4038.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sara De Dosso Breakdown of academic impact, for papers by Yuan‐Tzu Lan Breakdown of academic impact, for papers by Hisato Kawakami Breakdown of academic impact, for papers by Cristiana Lupi Breakdown of academic impact, for papers by J. Randolph Hecht Breakdown of academic impact, for papers by Katia Bencardino Breakdown of academic impact, for papers by Syma Iqbal Breakdown of academic impact, for papers by Emily Chan Breakdown of academic impact, for papers by Frédérique Penault–Llorca Breakdown of academic impact, for papers by Fabio Gelsomino